On May 16, 2019, IVI was honored to receive a delegation from China National Biotec Group Company Limited (CNBG), China’s biggest vaccine manufacturer. Led by its President, Mr. WU Yonglin, CNBG and IVI discussed possibilities for collaborating to increase the impact of CNBG’s vaccines on global health. Potential future projects include product development and delivery, support on clinical trials, capacity building and training.
Dr. Jerome Kim, Director General of IVI and Mr. WU Yonglin, President of CNBG
CNBG is the biological product arm of Sinopharm, China’s largest pharmaceutical and healthcare group, with core business interests in pharmaceutical distribution, scientific research, and the manufacture of medical and biotech products. CNBG is the leading vaccine manufacturer in China, having multiple production sites in 8 major Chinese cities, focusing on R&D, manufacture and marketing of biological products.
“Working towards a world free of suffering from infectious diseases is a joint effort and IVI greatly values the importance of this collaboration,” IVI Director General Dr. Jerome Kim told the eight-member CNBG delegation. “Bringing different sectors and partners together to enable vaccine development and delivery is truly pivotal to improving global public health.”
IVI is looking forward to further developing a mutually beneficial and fruitful partnership with CNBG in order to improve the health and well being of adults and children in developing countries.